Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 4Stomach Neoplasms 2Neoplasms 2Multiple Myeloma 2Lymphoma 2Lung Neoplasms 2Hematologic Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Non-Small-Cell Lung 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Recurrent Squamous Cell Lung Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Muscle Invasive Bladder Cancer 1Melanoma 1Glioma 1FGFR1 Gene Amplification 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 92Gemcitabine 56Nivolumab 50Cisplatin 39atezolizumab 37Carboplatin 30avelumab 29enfortumab vedotin 26Docetaxel 23Magnetic Resonance Spectroscopy 19Mitomycin 17Ipilimumab 17Paclitaxel 16Specimen Handling 14durvalumab 11toripalimab 10sacituzumab govitecan 10Pemetrexed 10cabozantinib 9Taxes 8vinflunine 7Cyclophosphamide 7tislelizumab 6Injections 6Bevacizumab 6pemigatinib 5fludarabine 5disitamab vedotin 5Standard of Care 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × AZD4547 × Clear all
NCT05775874 2023-03-20

A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC

Abbisko Therapeutics Co, Ltd

Phase 2 Unknown
80 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT05086666 2021-10-21

A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547

Abbisko Therapeutics Co, Ltd

Phase 1/2 Unknown
108 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡